SCHEMBL2155535

SCHEMBL2155535

Cc1cccc2c1C(=O)C(CN(C(=O)O)c1cccc(C(F)(F)F)c1)(CN(C(=O)O)c1cccc(C(F)(F)F)c1)CS2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.38
RXFP1 Q9HBX9 2/20 0.38
TP53 P04637 1/20 0.38
POLB P06746 1/20 0.38
NR1H4 Q96RI1 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35
HTT P42858 3/20 0.35
GAA P10253 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
LTB4R2 Q9NPC1 2/20 0.34
LMNA P02545 1/20 0.34
HDAC1 Q13547 4/20 0.33
HDAC6 Q9UBN7 4/20 0.33
HDAC8 Q9BY41 3/20 0.33
HPGD P15428 1/20 0.33
HDAC5 Q9UQL6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2155960 0.87 ALDH1A1 (0.35) TP53CYP1A2CYP3A4CYP2C19HTT
SCHEMBL2156970 0.82 LMNA (0.37) RXFP1TP53CYP1A2CYP3A4CYP2C19
SCHEMBL2156194 0.77 MEN1 (0.36) MAPTRXFP1TP53CYP1A2CYP3A4
SCHEMBL2156975 0.76 MEN1 (0.37) MAPTRXFP1TP53CYP1A2CYP3A4
SCHEMBL2155996 0.74 GAA (0.38) MAPTCYP1A2CYP3A4CYP2C19GAA
SCHEMBL2155647 0.69 TAS2R14 (0.36) CYP3A4GAANPSR1KMT2AHDAC6
SCHEMBL2156805 0.69 MYC (0.34) CYP3A4HTTGAANPSR1KMT2A
SCHEMBL4437768 0.65 MEN1 (0.54) MAPTRXFP1CYP1A2CYP3A4CYP2C19
SCHEMBL2157148 0.65 KDM4E (0.34) TP53
SCHEMBL20357360 0.64 MEN1 (0.44) MAPTCYP1A2CYP3A4CYP2C19HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973072-B2 Pain, eating disorders, neurodegenerative disorders, memory impairment; attention deficit syndrome, opioid tolerance, drug addiction; (4-oxothiochroman-3,3-diyl)bis(methylene)bis(3-(trifluoromethyl)benzoate for example GRUENENTHAL GMBH (DE) 2011-07-05 US claimed
US-7973072-B2 Pain, eating disorders, neurodegenerative disorders, memory impairment; attention deficit syndrome, opioid tolerance, drug addiction; (4-oxothiochroman-3,3-diyl)bis(methylene)bis(3-(trifluoromethyl)benzoate for example GRUENENTHAL GMBH (DE) 2011-07-05 US disclosed